via IBM Research
Antibiotic resistance is no joke. It’s a huge threat to human health — even more so during the raging pandemic. We need new antibiotics, and we need them fast.
In the US alone, nearly three million people¹ get infected with antibiotic-resistant bacteria or fungi every year¹. But very few new antibiotics are being developed to replace those that no longer work. That’s because drug design is an extremely difficult and lengthy process — there are more possible chemical combinations of a new molecule than there are atoms in the Universe.
We want to help.
Paving the way to the era of Accelerated Discovery, our IBM Research team has developed an AI system that can help speed up the design of molecules for novel antibiotics. And it works — in “Accelerating Antimicrobial Discovery with Controllable Deep Generative Models and Molecular Dynamics,” published in Nature Biomedical Engineering, we outline how we used it to create two new non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum potency. Peptides are small molecules — they are short strings of amino acids, the building blocks of proteins. Our approach outperforms other leading de novo AMP design methods by nearly 10 percent.
Beyond antibiotics, this generative AI system could potentially accelerate the design process of the best possible molecules for new drugs and materials — helping scientists to use AI to discover and design better candidates for more effective drugs and therapies for diseases, materials to absorb and capture carbon to help fight climate change, materials for more intelligent energy production and storage, and much more. To fight these challenges, we need to accelerate the rate of discovery of new and functional molecules — at scale.
Where is that molecule?
That’s far from easy. Zeroing in on the correct molecular configuration that would lead to a new material with desired properties among the astronomical number of possible molecules is like looking for a needle in a haystack. For peptides, one would typically have to experimentally screen more than a hundred molecules to find one with the right properties.
So we’ve turned to AI for help.
First, we used an AI generative model dubbed a deep generative autoencoder to learn about the vast space of known peptide molecules. The model captured meaningful information such as molecular similarity and function about diverse peptide sequences, enabling us to explore beyond known antimicrobial templates.
We then applied Controlled Latent attribute Space Sampling (CLaSS) — a recently developed computational method for generating novel peptide molecules with custom properties. It works by sampling from the informative latent space of peptides and relies on a rejection sampling scheme guided by the molecular property the classifier trained on during the latent representation. Since CLaSS performs attribute-conditioned sampling in the compressed latent space, it is a computationally efficient and scalable approach that can be easily repurposed.
We then used deep learning classifiers to screen the AI-generated candidate antimicrobial molecules for additional key attributes, such as toxicity and broad-spectrum activity. We performed additional screening with the help of high-throughput, coarse-grained molecular dynamics simulations. These simulations look for presence of novel physicochemical features indicative of stable and peptide-membrane binding, such as low-contact variance between peptide and membrane.
Within 48 days, our AI-boosted molecular design approach to Accelerated Discovery enabled us to identify, synthesize, and experimentally test 20 AI-generated novel candidate antimicrobial peptides. Two of them turned out to be highly potent against diverse Gram-positive and Gram-negative pathogens (including multidrug-resistant K. pneumoniae) and very unlikely to trigger drug resistance in E. coli.
We also didn’t find any cross-resistance for either of the AMPs when tested using a polymyxin-resistant strain. Live-cell confocal imaging showed the formation of membrane pores as the underlying mechanism of bactericidal mode of action of these peptides. Both antimicrobials have low toxicity — we tested them in vitro and also in mice, providing important information about the safety, toxicity and efficacy of these antimicrobial candidates in a complex animal model.
Our proposed approach could potentially lead to faster and more efficient discovery of potent and selective broad-spectrum antimicrobials to keep antibiotic-resistant bacteria at bay — for good. And we hope that our AI could also be used to help address the world’s other most difficult discovery challenges, such as designing new therapeutics, environmentally friendly and sustainable photoresists, new catalysts for more efficient carbon capture, and so much more.
Original Article: IBM AI finds new peptides – paving the way to better drug design
More from: IBM Research
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- New data shows dog respiratory illness up in Canada, Nevada. Experts say treat it like a human cold
Data released by Trupanion shows that respiratory illness case claims have gone up in several territories including in Canada. Experts break the data down.
- New report reveals antibiotic underdosing could be leading cause of AMR in UK
A new report conducted by the office of Baroness Bennett of Manor Castle has revealed an underdelivery of IV antibiotics, which could be a leading cause of antimicrobial resistance (AMR) in the UK.
- Antibiotic Evolution Insights May Lead to New Drug Development
Scientists from the University of Tübingen and Monash University studied glycopeptide antibiotics, a key resource in countering drug-resistant pathogens, to uncover their evolutionary origins to gain ...
- New Bacterial Identification Method Could Help Reduce Use of Antibiotics
Researchers have developed a method that identifies bacteria easily, cheaply and more precisely than before. This can help reduce use of antibiotics.
- One dose of antibiotics a year ‘raises risk of sepsis by 70 per cent’
A single course of antibiotics raises the risk of developing sepsis by 70 per cent for a year after taking them, a new study of NHS patients has revealed.
Go deeper with Google Headlines on:
[google_news title=”” keyword=”new antibiotics” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- Opinion: What the promise of lower drug prices would mean for Utah’s patients
Lower drug prices, particularly those for chronic conditions, is a pressing need for many retirees and patients on Medicare living in Utah. Read more.
- The harms of excessive use of antibiotics
ALBAWABA - Excessive antibiotic consumption is posing a dire threat to public health, warned the European branch of the World Health Organization (WHO). The misuse of antibiotics is contributing to ...
- Game-Changer: Swift Bacteria Identification Method to Cut Antibiotic Use
Amid growing concerns over antibiotic resistance, a groundbreaking development has emerged, offering hope in the fight against bacterial infections. Researchers have unveiled an innovative method for ...
- A drug is in development to help big dogs live longer. Here's what we know
Halioua is not yet making any claims for exactly how much longer it could extend a dog's life. They are still working on that data, but the goal is at least one year. The theory is that if the dog is ...
- AI Revolutionizes Pharmaceutical Research: Accelerating Drug Development
In the fast-evolving landscape of generative artificial intelligence (AI), the pharmaceutical industry is experiencing groundbreaking advancements in the development of new drugs. Researchers at ETH ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”antibiotic development” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]